Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) and Novartis (NYSE:NVS – Get Free Report) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, analyst recommendations, profitability, earnings and risk.
Analyst Ratings
This is a breakdown of current ratings for Neurocrine Biosciences and Novartis, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Neurocrine Biosciences | 0 | 4 | 19 | 1 | 2.88 |
| Novartis | 3 | 9 | 6 | 0 | 2.17 |
Neurocrine Biosciences presently has a consensus price target of $202.59, indicating a potential upside of 21.02%. Novartis has a consensus price target of $152.25, indicating a potential downside of 5.19%. Given Neurocrine Biosciences’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Neurocrine Biosciences is more favorable than Novartis.
Risk and Volatility
Insider and Institutional Ownership
92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 0.0% of Novartis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Neurocrine Biosciences and Novartis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Neurocrine Biosciences | 18.98% | 23.39% | 16.22% |
| Novartis | 18.11% | 41.04% | 14.45% |
Valuation & Earnings
This table compares Neurocrine Biosciences and Novartis”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Neurocrine Biosciences | $2.86 billion | 5.92 | $478.60 million | $6.74 | 24.84 |
| Novartis | $54.53 billion | 5.62 | $13.98 billion | $5.24 | 30.65 |
Novartis has higher revenue and earnings than Neurocrine Biosciences. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.
Summary
Neurocrine Biosciences beats Novartis on 10 of the 15 factors compared between the two stocks.
About Neurocrine Biosciences
Neurocrine Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for neurological, endocrine and related disorders. Founded in 1992 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed medicines include INGREZZA (valbenazine), approved in the United States for tardive dyskinesia and chorea associated with Huntington disease, and CRENESSITY (crinecerfont), used with glucocorticoid replacement therapy to treat classic congenital adrenal hyperplasia in adults and children.
About Novartis
Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company’s medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
